See more : SVF Investment Corp. 3 (SVFC) Income Statement Analysis – Financial Results
Complete financial analysis of Bristol-Myers Squibb Company (BMY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bristol-Myers Squibb Company, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Chichibu Railway Co., Ltd. (9012.T) Income Statement Analysis – Financial Results
- Alm. Brand A/S (ALMB.CO) Income Statement Analysis – Financial Results
- Minera Frisco, S.A.B. de C.V. (MFRVF) Income Statement Analysis – Financial Results
- Hanjin Kal (18064K.KS) Income Statement Analysis – Financial Results
- Shenzhen keanda electronic technology co.,ltd (002972.SZ) Income Statement Analysis – Financial Results
Bristol-Myers Squibb Company (BMY)
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.01B | 46.16B | 46.39B | 42.52B | 26.15B | 22.56B | 20.78B | 19.43B | 16.56B | 15.88B | 16.39B | 17.62B | 21.24B | 19.48B | 18.81B | 20.60B | 19.35B | 17.91B | 19.21B | 19.38B | 20.89B | 18.12B | 19.42B | 18.22B | 20.22B | 18.28B | 16.70B | 15.07B | 13.77B | 11.98B | 11.41B | 11.16B | 11.16B | 10.30B | 9.19B | 8.56B | 7.56B |
| Cost of Revenue | 10.69B | 10.14B | 9.94B | 11.77B | 8.08B | 6.55B | 6.07B | 4.95B | 3.91B | 3.93B | 4.62B | 4.61B | 5.60B | 5.28B | 5.14B | 6.40B | 6.22B | 5.96B | 5.93B | 5.99B | 7.59B | 6.39B | 5.58B | 4.01B | 4.86B | 4.23B | 3.87B | 3.45B | 3.19B | 2.79B | 2.72B | 2.56B | 2.68B | 2.63B | 2.46B | 2.30B | 2.14B |
| Gross Profit | 34.31B | 36.02B | 36.45B | 30.75B | 18.07B | 16.01B | 14.71B | 14.48B | 12.65B | 11.95B | 11.77B | 13.01B | 15.65B | 14.21B | 13.67B | 14.20B | 13.13B | 11.96B | 13.28B | 13.39B | 13.30B | 11.73B | 13.85B | 14.20B | 15.36B | 14.05B | 12.83B | 11.62B | 10.58B | 9.19B | 8.69B | 8.59B | 8.48B | 7.67B | 6.73B | 6.26B | 5.42B |
| Gross Profit Ratio | 76.24% | 78.04% | 78.57% | 72.31% | 69.10% | 70.98% | 70.80% | 74.54% | 76.39% | 75.24% | 71.81% | 73.84% | 73.65% | 72.92% | 72.67% | 68.95% | 67.86% | 66.75% | 69.14% | 69.10% | 63.66% | 64.74% | 71.30% | 77.97% | 75.96% | 76.86% | 76.81% | 77.13% | 76.84% | 76.69% | 76.16% | 77.03% | 75.95% | 74.47% | 73.23% | 73.14% | 71.67% |
| Research & Development | 9.30B | 9.51B | 10.20B | 11.14B | 6.15B | 6.35B | 6.41B | 4.94B | 5.92B | 4.53B | 3.73B | 3.90B | 3.84B | 3.57B | 3.65B | 3.59B | 3.28B | 3.07B | 2.75B | 2.50B | 2.28B | 2.22B | 2.26B | 1.94B | 1.84B | 1.58B | 1.39B | 1.28B | 1.20B | 1.11B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.28B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 162.00M | 91.00M | 160.00M | 877.00M | 165.00M | 158.00M | 4.20B | 3.56B | 4.08B | 4.83B | 4.86B | 4.92B | 5.11B | 5.02B | 4.66B | 3.92B | 3.90B | 3.86B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.40B | 7.81B | 7.69B | 7.66B | 4.87B | 4.55B | 4.69B | 4.91B | 4.84B | 4.82B | 4.94B | 5.02B | 957.00M | 977.00M | 1.14B | 1.55B | 1.47B | 1.35B | 1.48B | 1.41B | 1.42B | 1.30B | 1.43B | 1.67B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.77B | 7.81B | 7.69B | 7.66B | 4.87B | 4.55B | 4.85B | 5.00B | 5.00B | 5.70B | 5.10B | 5.18B | 5.16B | 4.54B | 5.21B | 6.38B | 6.32B | 6.27B | 6.58B | 6.43B | 6.08B | 5.22B | 5.34B | 5.53B | 6.99B | 6.73B | 6.41B | 5.87B | 5.32B | 4.53B | 5.98B | 6.34B | 5.46B | 5.04B | 5.45B | 4.30B | 3.79B |
| Other Expenses | 0.00 | 9.60B | 10.02B | 9.76B | 1.14B | 1.37B | 1.40B | 1.00B | 621.00M | 313.00M | 133.00M | 245.00M | 0.00 | 284.00M | -931.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 746.00M | 678.00M | 625.00M | 591.00M | 519.00M | 448.00M | 328.00M | 308.00M | 295.00M | 246.00M | 244.00M | 196.00M | 185.00M | 161.00M |
| Operating Expenses | 34.31B | 26.92B | 27.91B | 28.57B | 12.15B | 10.90B | 11.26B | 9.94B | 10.92B | 10.23B | 8.84B | 9.08B | 8.61B | 7.71B | 8.86B | 8.48B | 9.60B | 9.34B | 9.33B | 8.93B | 8.36B | 7.44B | 7.60B | 8.22B | 9.51B | 8.93B | 8.39B | 7.67B | 6.96B | 5.97B | 6.29B | 6.63B | 5.71B | 5.28B | 5.65B | 4.49B | 3.95B |
| Cost & Expenses | 27.76B | 37.06B | 37.85B | 40.34B | 20.23B | 17.44B | 17.33B | 14.89B | 14.83B | 14.17B | 13.45B | 13.69B | 14.21B | 12.98B | 14.00B | 14.88B | 15.82B | 15.29B | 15.26B | 14.92B | 15.95B | 13.82B | 13.17B | 12.23B | 14.37B | 13.16B | 12.26B | 11.11B | 10.15B | 8.76B | 9.01B | 9.20B | 8.39B | 7.91B | 8.11B | 6.79B | 6.09B |
| Interest Income | 0.00 | 171.00M | 120.00M | 121.00M | 464.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 91.00M | 75.00M | 54.00M | 130.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.17B | 1.23B | 1.33B | 1.42B | 656.00M | 183.00M | 196.00M | 167.00M | 184.00M | 203.00M | 199.00M | 182.00M | 145.00M | 145.00M | 184.00M | 310.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 410.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 9.81B | 10.29B | 10.76B | 10.49B | 1.81B | 703.00M | 872.00M | 626.00M | 376.00M | 467.00M | 763.00M | 681.00M | 801.00M | 744.00M | 707.00M | 816.00M | 892.00M | 927.00M | 929.00M | 909.00M | 789.00M | 735.00M | 781.00M | 746.00M | 678.00M | 625.00M | 591.00M | 519.00M | 448.00M | 328.00M | 308.00M | 295.00M | 246.00M | 244.00M | 196.00M | 185.00M | 161.00M |
| EBITDA | 19.37B | 19.23B | 20.19B | 5.04B | 7.44B | 6.85B | 6.20B | 4.63B | 2.94B | 3.41B | 4.40B | 3.51B | 7.93B | 7.09B | 6.61B | 6.60B | 4.42B | 3.31B | 4.67B | 5.37B | 5.72B | 4.84B | 5.89B | 6.73B | 5.92B | 5.08B | 5.03B | 4.47B | 4.06B | 3.55B | 2.71B | 2.26B | 3.01B | 2.63B | 1.28B | 1.96B | 1.63B |
| EBITDA Ratio | 43.03% | 43.16% | 43.51% | 34.85% | 25.24% | 26.91% | 27.52% | 28.91% | 14.70% | 13.44% | 19.71% | 24.74% | 33.54% | 33.75% | 22.92% | 28.99% | 24.59% | 21.12% | 23.16% | 28.31% | 28.37% | 35.29% | 52.78% | 40.01% | 32.61% | 35.73% | 29.78% | 29.40% | 38.63% | 35.64% | 21.78% | 19.53% | 25.41% | 23.70% | 11.12% | 20.60% | 18.72% |
| Operating Income | 17.24B | 10.33B | 10.16B | 5.13B | 5.46B | 5.12B | 3.45B | 4.54B | 1.73B | 1.71B | 2.93B | 3.93B | 6.65B | 5.61B | 5.74B | 4.24B | 3.53B | 2.62B | 3.95B | 4.46B | 4.95B | 4.30B | 6.25B | 5.99B | 5.85B | 5.12B | 4.44B | 3.95B | 3.62B | 3.22B | 2.40B | 1.96B | 2.77B | 2.39B | 1.08B | 1.77B | 1.47B |
| Operating Income Ratio | 38.31% | 22.37% | 21.90% | 12.06% | 20.90% | 22.69% | 16.61% | 23.36% | 10.45% | 10.79% | 17.89% | 22.31% | 31.29% | 28.77% | 30.51% | 20.59% | 18.23% | 14.63% | 20.57% | 23.03% | 23.68% | 23.70% | 32.19% | 32.86% | 28.94% | 28.01% | 26.57% | 26.24% | 26.26% | 26.88% | 21.05% | 17.57% | 24.79% | 23.19% | 11.79% | 20.68% | 19.41% |
| Total Other Income/Expenses | -8.80B | -10.64B | -9.30B | -7.42B | -938.00M | -426.00M | -108.00M | 1.45B | 347.00M | 667.00M | -40.00M | -1.59B | 344.00M | 121.00M | 163.00M | -247.00M | 6.00M | 610.00M | 353.00M | -46.00M | -612.00M | -1.60B | -2.94B | -508.00M | -81.00M | -818.00M | 44.00M | 60.00M | -1.21B | -666.00M | 168.00M | 27.00M | 121.00M | 135.00M | 194.00M | 119.00M | 161.00M |
| Income Before Tax | 8.44B | 7.71B | 8.10B | -6.87B | 4.98B | 6.01B | 5.13B | 5.92B | 2.17B | 2.38B | 2.89B | 2.34B | 6.98B | 6.07B | 5.60B | 5.47B | 3.53B | 2.64B | 4.52B | 4.42B | 4.69B | 2.65B | 2.90B | 5.48B | 5.77B | 4.27B | 4.48B | 4.01B | 2.40B | 2.56B | 2.57B | 1.99B | 2.89B | 2.52B | 1.28B | 1.89B | 1.63B |
| Income Before Tax Ratio | 18.75% | 16.71% | 17.46% | -16.16% | 19.03% | 26.64% | 24.70% | 30.45% | 13.09% | 14.99% | 17.64% | 13.28% | 32.86% | 31.16% | 29.79% | 26.56% | 18.27% | 14.71% | 23.51% | 22.80% | 22.47% | 14.61% | 14.91% | 30.07% | 28.52% | 23.34% | 26.84% | 26.64% | 17.45% | 21.32% | 22.53% | 17.81% | 25.87% | 24.50% | 13.90% | 22.07% | 21.54% |
| Income Tax Expense | 400.00M | 1.37B | 1.08B | 2.12B | 1.52B | 1.03B | 4.16B | 1.41B | 477.00M | 352.00M | 311.00M | -161.00M | 1.72B | 1.56B | 1.18B | 1.32B | 803.00M | 610.00M | 932.00M | 1.52B | 1.22B | 435.00M | 459.00M | 1.38B | 1.60B | 1.13B | 1.28B | 1.16B | 590.00M | 713.00M | 612.00M | 449.00M | 831.00M | 776.00M | 530.00M | 635.00M | 560.00M |
| Net Income | 8.03B | 6.33B | 6.99B | -9.00B | 3.44B | 4.95B | 1.01B | 4.46B | 1.62B | 2.00B | 2.56B | 1.96B | 3.71B | 3.10B | 10.61B | 5.25B | 2.17B | 1.59B | 3.00B | 2.39B | 3.11B | 2.07B | 5.25B | 4.71B | 4.17B | 3.14B | 3.21B | 2.85B | 1.81B | 1.84B | 1.96B | 1.96B | 2.06B | 1.75B | 747.00M | 1.25B | 1.07B |
| Net Income Ratio | 17.83% | 13.71% | 15.08% | -21.16% | 13.15% | 21.95% | 4.85% | 22.94% | 9.81% | 12.62% | 15.64% | 11.12% | 17.46% | 15.92% | 56.42% | 25.47% | 11.19% | 8.85% | 15.62% | 12.32% | 14.87% | 11.40% | 27.00% | 25.86% | 20.61% | 17.18% | 19.19% | 18.92% | 13.16% | 15.37% | 17.16% | 17.59% | 18.42% | 16.97% | 8.13% | 14.65% | 14.13% |
| EPS | 3.88 | 2.97 | 3.15 | -3.98 | 2.02 | 3.03 | 0.61 | 2.67 | 0.97 | 1.21 | 1.56 | 1.17 | 2.18 | 1.81 | 5.38 | 2.65 | 1.10 | 0.81 | 1.54 | 1.23 | 1.60 | 1.03 | 2.70 | 2.40 | 2.10 | 1.58 | 1.61 | 1.42 | 0.90 | 0.90 | 0.95 | 0.96 | 0.99 | 0.84 | 0.36 | 0.60 | 0.50 |
| EPS Diluted | 3.86 | 2.95 | 3.12 | -3.98 | 2.01 | 3.03 | 0.61 | 2.65 | 0.97 | 1.20 | 1.54 | 1.16 | 2.16 | 1.80 | 5.37 | 2.62 | 1.09 | 0.81 | 1.51 | 1.21 | 1.59 | 1.02 | 2.67 | 2.36 | 2.06 | 1.55 | 1.57 | 1.40 | 0.89 | 0.90 | 0.95 | 0.96 | 0.99 | 0.84 | 0.36 | 0.60 | 0.50 |
| Weighted Avg Shares Out | 2.07B | 2.13B | 2.22B | 2.26B | 1.71B | 1.63B | 1.65B | 1.67B | 1.67B | 1.66B | 1.64B | 1.67B | 1.70B | 1.71B | 1.97B | 1.98B | 1.97B | 1.96B | 1.95B | 1.94B | 1.94B | 2.00B | 1.94B | 1.97B | 1.98B | 1.99B | 1.99B | 2.01B | 2.02B | 2.04B | 2.06B | 2.04B | 2.08B | 2.08B | 2.08B | 2.09B | 2.14B |
| Weighted Avg Shares Out (Dil) | 2.08B | 2.15B | 2.25B | 2.26B | 1.71B | 1.64B | 1.65B | 1.68B | 1.68B | 1.67B | 1.66B | 1.69B | 1.72B | 1.73B | 1.98B | 2.00B | 1.98B | 1.96B | 1.98B | 1.98B | 1.95B | 2.02B | 1.97B | 2.00B | 2.03B | 2.03B | 2.04B | 2.04B | 2.03B | 2.04B | 2.06B | 2.04B | 2.08B | 2.08B | 2.08B | 2.09B | 2.14B |
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
HC Wainwright has initiated coverage on Alumis Inc. ALMS, a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.
A Market Crash Could Ruin Baby Boomers: 5 Safe High-Yield Dividend Stocks and Advice
24/7 Wall St. Insights The 2025 Social Security COLA will be only 2.5%.
3 Dividend Stocks for October 2024
#Morningstar #VerizonStock #DividendStocks These three dividend payers have an average yield of more than 4.5%. 00:00 Introduction 00:10 Bristol-Myers Squibb BMY 00:45 Polaris PII 01:04 Verizon VZ David Harrell: Hi.
Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $52.20, denoting a -0.38% change from the preceding trading day.
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
While the recent spate of positive regulatory updates boosts Bristol Myers, we will advise a wait-and-watch strategy.
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol Myers Squibb: A High-Yield Bargain With Growth On The Horizon
Frequent trading can erode gains due to transaction costs and taxes; a buy-and-hold strategy is often more effective for retail investors. Bristol Myers Squibb offers a strong dividend yield, below-average valuation, and solid growth prospects, making it a compelling buy....
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
The latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close.
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--U.S. FDA Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo.
2 Passive-Income Stocks to Load Up On in October
These two dividend powerhouses are ideal choices for passive-income investors.
Source: https://incomestatements.info
Category: Stock Reports